Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P. Herishanu Y, et al. Among authors: shaulov a. Am J Hematol. 2020 Jun;95(6):604-611. doi: 10.1002/ajh.25766. Epub 2020 Mar 14. Am J Hematol. 2020. PMID: 32096887 Free article. Clinical Trial.
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. El-Galaly TC, et al. Among authors: shaulov a. Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477102 Free PMC article.
Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.
Inbar M, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Najib D, Rouvio O, Shaulov A, Greenbaum U, Polliack A, Tadmor T. Inbar M, et al. Among authors: shaulov a. Anticancer Res. 2018 Nov;38(11):6423-6429. doi: 10.21873/anticanres.13003. Anticancer Res. 2018. PMID: 30396967
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Goldschmidt N, Horowitz NA, Heffes V, Darawshy F, Mashiach T, Shaulov A, Gatt ME, Dann EJ. Goldschmidt N, et al. Among authors: shaulov a. Leuk Lymphoma. 2019 Aug;60(8):1890-1898. doi: 10.1080/10428194.2018.1564823. Epub 2019 Jan 28. Leuk Lymphoma. 2019. PMID: 30689468
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T, Levy I, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Dally N, Rouvio O, Shaulov A, Greenbaum U, Inbar M, Polliack A. Tadmor T, et al. Among authors: shaulov a. Leuk Res. 2019 Jul;82:24-28. doi: 10.1016/j.leukres.2019.05.006. Epub 2019 May 19. Leuk Res. 2019. PMID: 31152919
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Katodritou E, Kastritis E, Gatt M, Cohen YC, Avivi I, Pouli A, Lalayianni C, Lavi N, Delimpasis S, Kyrtsonis MC, Michael M, Suriu C, Miri Z, Tzafarti K, Vadikoliou C, Maltezas D, Zikos P, Ganzel C, Vaxman Y, Aviv A, Christoforidou A, Gavriatopoulou M, Shaulov A, Verrou E, Papanota AM, Fakinos G, Gkioka AI, Palaska V, Triantafyllou T, Konstantinidou P, Anagnostopoulos A, Terpos E, Dimopoulos MA. Katodritou E, et al. Among authors: shaulov a. Am J Hematol. 2020 May;95(5):465-471. doi: 10.1002/ajh.25755. Epub 2020 Mar 2. Am J Hematol. 2020. PMID: 32048329 Free article.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, Kreiniz N, Tadmor T, Trestman S, Vitkon R, Rouvio O, Shvetz O, Shaulov A, Ziv-Baran T, Avivi I. Cohen YC, et al. Among authors: shaulov a. Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32193630
78 results